Federal contract award
75A50124C00059
REDHILL BIOPHARMA LTD-OPAGANIB AS HOST-DIRECTED THERAPEUTIC FOR EBOLA VIRUS DISEASE
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $733.4K |
| Current contract value | $733.4K |
| Potential contract value / ceiling | $733.4K |
| Start date | Sep 27, 2024 |
| Current end date | Mar 31, 2026 |
| Potential end date | Mar 31, 2026 |
| Latest award activity | Sep 3, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 3, 2025 | P00001 | $0 | REDHILL BIOPHARMA LTD-OPAGANIB AS HOST-DIRECTED THERAPEUTIC FOR EBOLA VIRUS DISEASE |
| Sep 27, 2024 | 0 | $733.4K | REDHILL BIOPHARMA LTD-OPAGANIB AS HOST-DIRECTED THERAPEUTIC FOR EBOLA VIRUS DISEASE |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.